Key Points
- Director David Dalvey sold 25,000 shares on May 4 at an average price of $140.68 under a pre‑arranged Rule 10b5‑1 plan, generating ~$3.52M and leaving him with 65,000 shares (a 27.78% reduction).
- Celcuity’s PI3K/mTOR inhibitor gedatolisib reported a Phase III survival benefit versus a Novartis comparator in metastatic PIK3CA+ breast cancer, a potential major commercial and clinical catalyst if confirmed.
- Analyst sentiment is broadly positive—ten Buys, one Hold and one Sell with an average target of $134.50 and several firms raising targets (e.g., Needham to $157, Craig Hallum to $189)—though some coverage questions valuation after a recent large run‑up.
Celcuity, Inc. (NASDAQ:CELC - Get Free Report) Director Richard Buller sold 9,000 shares of the company's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the transaction, the director directly owned 6,760 shares of the company's stock, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Celcuity Trading Down 1.6%
CELC stock opened at $139.44 on Thursday. Celcuity, Inc. has a 1-year low of $9.51 and a 1-year high of $151.02. The firm has a market cap of $6.74 billion, a P/E ratio of -36.79 and a beta of 0.09. The business's 50 day moving average is $115.96 and its 200-day moving average is $103.90. The company has a current ratio of 10.55, a quick ratio of 10.55 and a debt-to-equity ratio of 3.20.
Celcuity (NASDAQ:CELC - Get Free Report) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.09. Equities analysts anticipate that Celcuity, Inc. will post -3.87 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several research firms have recently weighed in on CELC. Citigroup reiterated an "outperform" rating on shares of Celcuity in a research note on Monday. Wolfe Research reiterated an "outperform" rating and issued a $110.00 price objective on shares of Celcuity in a research note on Thursday, March 12th. Citizens Jmp upped their price objective on Celcuity from $150.00 to $160.00 and gave the company a "market outperform" rating in a research note on Monday. Guggenheim upped their price objective on Celcuity from $135.00 to $165.00 and gave the company a "buy" rating in a research note on Monday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Celcuity in a research report on Monday, April 20th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Celcuity has a consensus rating of "Moderate Buy" and a consensus target price of $134.50.
View Our Latest Analysis on Celcuity
Institutional Investors Weigh In On Celcuity
Large investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC grew its position in Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company's stock worth $34,000 after acquiring an additional 319 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in Celcuity during the 4th quarter worth approximately $42,000. Ogorek Anthony Joseph NY ADV bought a new stake in Celcuity during the 3rd quarter worth approximately $27,000. US Bancorp DE grew its position in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company's stock worth $35,000 after acquiring an additional 143 shares during the last quarter. Finally, NBC Securities Inc. bought a new stake in Celcuity during the 4th quarter worth approximately $99,000. 63.33% of the stock is currently owned by institutional investors.
Celcuity News Summary
Here are the key news stories impacting Celcuity this week:
- Positive Sentiment: Phase III clinical success — Celcuity’s PI3K/mTOR inhibitor gedatolisib showed a survival benefit and outperformed a Novartis comparator in a Phase III metastatic PIK3CA+ breast cancer study, providing a major commercial/clinical catalyst if confirmed and advancing the company’s drug‑development thesis. Gedatolisib Improves Survival Gedatolisib Beats Novartis
- Positive Sentiment: Analyst support — Guggenheim reiterated a Buy rating on CELC, which can reinforce investor confidence and provide buying support following the clinical readout. Guggenheim Keeps Their Buy Rating on Celcuity (CELC)
- Neutral Sentiment: HC Wainwright model updates — the firm trimmed near‑term quarterly EPS forecasts (Q1–Q3 and Q2 2026 nudged lower) but raised Q4 2026 and materially lifted FY2027–FY2030 long‑range estimates (FY2030 raised sharply to $16.69). This is a mixed signal: short‑term profitability remains negative, but the research note increases long‑term upside assumptions that investors may price in. (Research note summary)
- Neutral Sentiment: Market commentary on valuation — coverage questioning whether CELC is still worth buying after a large run‑up has appeared, which can temper momentum as some investors reassess risk/reward. Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge?
- Negative Sentiment: Insider sales under 10b5‑1 plans — Director Richard Buller sold 9,000 shares (~$1.26M) and Director David Dalvey sold 25,000 shares (~$3.52M) at ~ $140.5 on May 4; both transactions were disclosed on Form 4s and executed under pre‑arranged 10b5‑1 plans. Planned insider selling can create short‑term selling pressure or signal liquidity events even though 10b5‑1 plans reduce information asymmetry. Buller Form 4 Dalvey Form 4
About Celcuity
(
Get Free Report)
Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.
Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
